These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7603014)

  • 41. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
    Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
    Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.
    Wall ME; Wani MC
    Cancer Res; 1995 Feb; 55(4):753-60. PubMed ID: 7850785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
    Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
    McDaid HM; Lopez-Barcons L; Grossman A; Lia M; Keller S; Pérez-Soler R; Horwitz SB
    Cancer Res; 2005 Apr; 65(7):2854-60. PubMed ID: 15805287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.
    Jang SH; Wientjes MG; Au JL
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1035-42. PubMed ID: 11181938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
    Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
    Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Hoffman RM
    Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
    Liao Y; Zou YY; Xia WY; Hung MC
    Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
    Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of new antimitotic antibiotics, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro.
    Ootsu K; Kozai Y; Takeuchi M; Ikeyama S; Igarashi K; Tsukamoto K; Sugino Y; Tashira T; Tsukagoshi S; Sakurai Y
    Cancer Res; 1980 May; 40(5):1707-17. PubMed ID: 6245801
    [No Abstract]   [Full Text] [Related]  

  • 51. New drug screen assay uses fewer mice, while cutting costs.
    Anderson LF
    J Natl Cancer Inst; 1995 Aug; 87(16):1213-4. PubMed ID: 7563166
    [No Abstract]   [Full Text] [Related]  

  • 52. What is the optimal rodent model for anti-tumor drug testing?
    Kerbel RS
    Cancer Metastasis Rev; 1998-1999; 17(3):301-4. PubMed ID: 10352884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orthotopic models are necessary to predict therapy of transplantable tumors in mice.
    Killion JJ; Radinsky R; Fidler IJ
    Cancer Metastasis Rev; 1998-1999; 17(3):279-84. PubMed ID: 10352881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Trials, tribulations, and trends in tumor modeling in mice.
    Schuh JC
    Toxicol Pathol; 2004; 32 Suppl 1():53-66. PubMed ID: 15209404
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The meaning and prospect of chemosensitivity tests].
    Kojima A; Saijo N
    Rinsho Byori; 1989 Jul; (Spec No 82):98-105. PubMed ID: 2693769
    [No Abstract]   [Full Text] [Related]  

  • 56. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer).
    Rosenberg MP; Bortner D
    Cancer Metastasis Rev; 1998-1999; 17(3):295-9. PubMed ID: 10352883
    [No Abstract]   [Full Text] [Related]  

  • 57. Ineffectiveness of five compounds on spontaneous mammary tumors of mice.
    CRANSTON EM
    Cancer Chemother Rep; 1963 Mar; 27():11-2. PubMed ID: 14023687
    [No Abstract]   [Full Text] [Related]  

  • 58. Rodent tumor models for anti-cancer drug testing: an overview.
    Kerbel RS
    Cancer Metastasis Rev; 1998-1999; 17(3):261. PubMed ID: 10352878
    [No Abstract]   [Full Text] [Related]  

  • 59. Reply to the editorial 'of seaweed, mice, and men'.
    Berger DP; Henss H; Winterhalter BR; Fiebig HH
    Ann Oncol; 1991 Jan; 2(1):72-3. PubMed ID: 2009239
    [No Abstract]   [Full Text] [Related]  

  • 60. [Production of mammary tumors by an allenolic acid derivative in male mice].
    RUDALL G
    C R Seances Soc Biol Fil; 1952 Jun; 146(11-12):916-8. PubMed ID: 12998304
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.